We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Leidos (LDOS) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Leidos (LDOS - Free Report) is expected to reveal quarterly earnings of $1.73 per share, indicating a decline of 5.5% compared to the year-ago period. Analysts forecast revenues of $3.79 billion, representing an increase of 2.5% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Leidos metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues- Defense Solutions' stands at $2.16 billion. The estimate indicates a year-over-year change of +4.5%.
Based on the collective assessment of analysts, 'Revenues- Health' should arrive at $716.82 million. The estimate indicates a change of +3.7% from the prior-year quarter.
Analysts predict that the 'Revenues- Civil' will reach $936.27 million. The estimate suggests a change of -0.2% year over year.
Analysts forecast 'Operating Income- Non-GAAP- Defense Solutions' to reach $184.59 million. Compared to the current estimate, the company reported $177 million in the same quarter of the previous year.
Analysts' assessment points toward 'Operating Income- Non-GAAP- Health' reaching $123.64 million. The estimate compares to the year-ago value of $99 million.
The collective assessment of analysts points to an estimated 'Operating Income- Non-GAAP- Civil' of $94.69 million. The estimate is in contrast to the year-ago figure of $105 million.
Over the past month, shares of Leidos have returned +3.1% versus the Zacks S&P 500 composite's +6.5% change. Currently, LDOS carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Leidos (LDOS) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
The upcoming report from Leidos (LDOS - Free Report) is expected to reveal quarterly earnings of $1.73 per share, indicating a decline of 5.5% compared to the year-ago period. Analysts forecast revenues of $3.79 billion, representing an increase of 2.5% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Leidos metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues- Defense Solutions' stands at $2.16 billion. The estimate indicates a year-over-year change of +4.5%.
Based on the collective assessment of analysts, 'Revenues- Health' should arrive at $716.82 million. The estimate indicates a change of +3.7% from the prior-year quarter.
Analysts predict that the 'Revenues- Civil' will reach $936.27 million. The estimate suggests a change of -0.2% year over year.
Analysts forecast 'Operating Income- Non-GAAP- Defense Solutions' to reach $184.59 million. Compared to the current estimate, the company reported $177 million in the same quarter of the previous year.
Analysts' assessment points toward 'Operating Income- Non-GAAP- Health' reaching $123.64 million. The estimate compares to the year-ago value of $99 million.
The collective assessment of analysts points to an estimated 'Operating Income- Non-GAAP- Civil' of $94.69 million. The estimate is in contrast to the year-ago figure of $105 million.
View all Key Company Metrics for Leidos here>>>
Over the past month, shares of Leidos have returned +3.1% versus the Zacks S&P 500 composite's +6.5% change. Currently, LDOS carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>